Effects of Different Antidiabetic Medications on Endothelial Glycocalyx, Myocardial Function, and Vascular Function in Type 2 Diabetic Patients: One Year Follow-Up Study.
arterial stiffness
endothelial glycocalyx
glycaemic control
left ventricular function
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
05 Jul 2019
05 Jul 2019
Historique:
received:
24
05
2019
revised:
24
06
2019
accepted:
03
07
2019
entrez:
10
7
2019
pubmed:
10
7
2019
medline:
10
7
2019
Statut:
epublish
Résumé
Poor glycaemic control affects myocardial function. We investigated changes in endothelial function and left ventricular (LV) myocardial deformation in poorly controlled type 2 diabetics before and after glycaemic control intensification. In 100 poorly-controlled diabetic patients (age: 51 ± 12 years), we measured at baseline and at 12 months after intensified glycaemic control: (a) Pulse wave velocity (PWV, Complior); (b) flow-mediated dilatation (FMD, %) of the brachial artery; (c) perfused boundary region (PBR) of the sublingual arterial micro-vessels (side-view dark-field imaging, Glycocheck); (d) LV global longitudinal strain (GLS), peak twisting (pTw), peak twisting velocity (pTwVel), and peak untwisting velocity (pUtwVel) using speckle tracking echocardiography, where the ratio of PWV/GLS was used as a marker of ventricular-arterial interaction; and (e) Malondialdehyde (MDA) and protein carbonyls (PCs) plasma levels. Intensified 12-month antidiabetic treatment reduced HbA1c (8.9 ± 1.8% (74 ± 24 mmol/mol) versus 7.1 ± 1.2% (54 ± 14 mmol/mol), Intensified glycaemic control, in addition to incretin-based treatment, improves arterial stiffness, endothelial glycocalyx, and myocardial deformation in type 2 diabetes after one year of treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Poor glycaemic control affects myocardial function. We investigated changes in endothelial function and left ventricular (LV) myocardial deformation in poorly controlled type 2 diabetics before and after glycaemic control intensification.
METHODS
METHODS
In 100 poorly-controlled diabetic patients (age: 51 ± 12 years), we measured at baseline and at 12 months after intensified glycaemic control: (a) Pulse wave velocity (PWV, Complior); (b) flow-mediated dilatation (FMD, %) of the brachial artery; (c) perfused boundary region (PBR) of the sublingual arterial micro-vessels (side-view dark-field imaging, Glycocheck); (d) LV global longitudinal strain (GLS), peak twisting (pTw), peak twisting velocity (pTwVel), and peak untwisting velocity (pUtwVel) using speckle tracking echocardiography, where the ratio of PWV/GLS was used as a marker of ventricular-arterial interaction; and (e) Malondialdehyde (MDA) and protein carbonyls (PCs) plasma levels.
RESULTS
RESULTS
Intensified 12-month antidiabetic treatment reduced HbA1c (8.9 ± 1.8% (74 ± 24 mmol/mol) versus 7.1 ± 1.2% (54 ± 14 mmol/mol),
CONCLUSIONS
CONCLUSIONS
Intensified glycaemic control, in addition to incretin-based treatment, improves arterial stiffness, endothelial glycocalyx, and myocardial deformation in type 2 diabetes after one year of treatment.
Identifiants
pubmed: 31284526
pii: jcm8070983
doi: 10.3390/jcm8070983
pmc: PMC6678085
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Diabetes Care. 2001 Jan;24(1):5-10
pubmed: 11194240
J Am Coll Cardiol. 2001 Jun 1;37(7):1943-9
pubmed: 11401136
Diabetes Care. 2002 Nov;25(11):2058-64
pubmed: 12401757
J Biochem Mol Toxicol. 2003;17(1):24-38
pubmed: 12616644
Endocr Rev. 2004 Aug;25(4):543-67
pubmed: 15294881
Heart. 2004 Dec;90(12):1483-4
pubmed: 15547039
Diabetologia. 2005 Feb;48(2):394-402
pubmed: 15645206
Diabetes. 2006 Feb;55(2):480-6
pubmed: 16443784
J Card Fail. 2006 Aug;12(6):458-63
pubmed: 16911913
J Hum Hypertens. 2007 Aug;21(8):654-63
pubmed: 17460710
Cell Biochem Biophys. 2007;49(2):65-72
pubmed: 17906361
Am J Hypertens. 2008 Jul;21(7):806-13
pubmed: 18497732
Diabetologia. 2008 Sep;51(9):1581-93
pubmed: 18607561
Eur J Heart Fail. 2009 Jan;11(1):39-47
pubmed: 19147455
Am J Cardiol. 2009 Apr 15;103(8):1134-8
pubmed: 19361602
Methods Enzymol. 1990;186:464-78
pubmed: 1978225
Mediators Inflamm. 2010;2010:792393
pubmed: 20634940
Diabetologia. 2010 Dec;53(12):2646-55
pubmed: 20865240
Eur J Cardiovasc Prev Rehabil. 2011 Dec;18(6):775-89
pubmed: 21450600
Cardiovasc Diabetol. 2011 Dec 20;10:113
pubmed: 22185563
Cardiovasc Diabetol. 2012 Oct 12;11:127
pubmed: 23062182
J Am Soc Nephrol. 2012 Nov;23(11):1900-8
pubmed: 23085635
Eur J Heart Fail. 2013 Feb;15(2):185-93
pubmed: 23099356
Can J Cardiol. 2013 Mar;29(3):317-28
pubmed: 23439018
Eur Heart J. 2013 Oct;34(39):3035-87
pubmed: 23996285
Circ Cardiovasc Imaging. 2014 Jul;7(4):619-28
pubmed: 24782115
J Card Fail. 2015 Jan;21(1):2-8
pubmed: 25451709
Can J Cardiol. 2015 Mar;31(3):287-95
pubmed: 25660150
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Cardiovasc Diabetol. 2015 Apr 17;14:37
pubmed: 25889250
Heart. 2015 Jul;101(13):1061-6
pubmed: 25935767
Circ Cardiovasc Imaging. 2016 Mar;9(3):e003643
pubmed: 26962125
Cardiovasc Diabetol. 2016 Mar 24;15:51
pubmed: 27013319
Int J Cardiol. 2017 Apr 15;233:105-112
pubmed: 28096045
Cardiovasc Diabetol. 2017 Sep 15;16(1):114
pubmed: 28915818
Cardiovasc Diabetol. 2018 Jan 8;17(1):8
pubmed: 29310645
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Eur J Clin Invest. 2019 Feb;49(2):e13049
pubmed: 30422317
Eur J Heart Fail. 2019 Apr;21(4):402-424
pubmed: 30859669
Acta Diabetol. 1995 Jun;32(2):110-5
pubmed: 7579531
Acta Diabetol. 1994 Sep;31(3):147-50
pubmed: 7827353
Clin Chem. 1997 Jul;43(7):1209-14
pubmed: 9216458